Business Description
Hunan Fangsheng Pharmaceutical Co Ltd
ISIN : CNE100001VG6
Total Employee Number:
1,868Compare
Compare
Traded in other countries / regions
603998.China Index Membership
SSE Composite Index IPO Date
2014-12-05Description
Hunan Fangsheng Pharmaceutical Co Ltd is engaged in pharmaceutical business. The company's business scope covers the production and sales of tablets, capsules, granules, oral suspension, powder, suppository, powder-injection, tinctures, spray lotion, small volume injections, and bulk pharmaceutical chemicals. Its product offerings include Cefixime Tablets, Cefpiramide for Injection, Cefprozil Tablets, Fleroxacin Dispersible Tablets, and others.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.63 | |||||
Equity-to-Asset | 0.57 | |||||
Debt-to-Equity | 0.23 | |||||
Debt-to-EBITDA | 1.09 | |||||
Interest Coverage | 27.3 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 3.48 | |||||
Beneish M-Score | -2.79 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -1.2 | |||||
3-Year EBITDA Growth Rate | 1.2 | |||||
3-Year EPS without NRI Growth Rate | 33.4 | |||||
3-Year FCF Growth Rate | 28.9 | |||||
3-Year Book Growth Rate | 7.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 19.79 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 11.34 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 92.82 | |||||
9-Day RSI | 82.05 | |||||
14-Day RSI | 72.54 | |||||
3-1 Month Momentum % | -7.66 | |||||
6-1 Month Momentum % | -20.32 | |||||
12-1 Month Momentum % | -10.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.9 | |||||
Quick Ratio | 0.59 | |||||
Cash Ratio | 0.23 | |||||
Days Inventory | 276.18 | |||||
Days Sales Outstanding | 55.16 | |||||
Days Payable | 148.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.79 | |||||
Dividend Payout Ratio | 0.54 | |||||
3-Year Dividend Growth Rate | 13.4 | |||||
Forward Dividend Yield % | 4.64 | |||||
5-Year Yield-on-Cost % | 12.78 | |||||
Shareholder Yield % | 8 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 73.18 | |||||
Operating Margin % | 19.32 | |||||
Net Margin % | 17.11 | |||||
EBITDA Margin % | 20.68 | |||||
FCF Margin % | 18.74 | |||||
OCF Margin % | 24.73 | |||||
ROE % | 18.2 | |||||
ROA % | 9.98 | |||||
ROIC % | 11.44 | |||||
3-Year ROIIC % | 23.5 | |||||
ROC (Joel Greenblatt) % | 32.25 | |||||
ROCE % | 19.4 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 15.4 | |||||
Forward PE Ratio | 12.88 | |||||
PE Ratio without NRI | 16.61 | |||||
Shiller PE Ratio | 29.94 | |||||
Price-to-Owner-Earnings | 26.82 | |||||
PEG Ratio | 0.76 | |||||
PS Ratio | 2.6 | |||||
PB Ratio | 2.73 | |||||
Price-to-Tangible-Book | 3.89 | |||||
Price-to-Free-Cash-Flow | 14.05 | |||||
Price-to-Operating-Cash-Flow | 10.65 | |||||
EV-to-EBIT | 12.3 | |||||
EV-to-EBITDA | 12.3 | |||||
EV-to-Revenue | 2.54 | |||||
EV-to-FCF | 13.57 | |||||
Price-to-GF-Value | 0.89 | |||||
Price-to-Projected-FCF | 1.83 | |||||
Price-to-DCF (Earnings Based) | 0.8 | |||||
Price-to-DCF (FCF Based) | 0.45 | |||||
Price-to-Median-PS-Value | 0.94 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.66 | |||||
Price-to-Graham-Number | 1.69 | |||||
Earnings Yield (Greenblatt) % | 8.13 | |||||
FCF Yield % | 7.09 | |||||
Forward Rate of Return (Yacktman) % | 21.93 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hunan Fangsheng Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,791.132 | ||
| EPS (TTM) (Â¥) | 0.7 | ||
| Beta | 0.798 | ||
| 3-Year Sharpe Ratio | -0.05 | ||
| 3-Year Sortino Ratio | -0.06 | ||
| Volatility % | 22.7 | ||
| 14-Day RSI | 72.54 | ||
| 14-Day ATR (Â¥) | 0.347533 | ||
| 20-Day SMA (Â¥) | 9.598 | ||
| 12-1 Month Momentum % | -10.59 | ||
| 52-Week Range (Â¥) | 8.64 - 13.5 | ||
| Shares Outstanding (Mil) | 439.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hunan Fangsheng Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hunan Fangsheng Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.150000 Cash Dividend | 2026-05-29 | 9.92 (-1.59%) | ||
| CNY 0.150000 Cash Dividend | 2026-01-16 | 11.90 (+0.59%) | ||
| CNY 0.150000 Cash Dividend | 2025-09-18 | 11.28 (-1.57%) | ||
| CNY 0.200000 Cash Dividend | 2025-06-09 | 10.48 (-0.66%) | ||
| CNY 0.060000 Cash Dividend | 2025-03-05 | 9.47 (-0.53%) | ||
| CNY 0.050000 Cash Dividend | 2024-10-21 | 12.61 (-0.08%) | ||
| 3:1 Stock Split | 2016-05-05 | 16.21 (+2.59%) | ||
| 1.3:1 Stock Split | 2015-04-17 | 12.44 (+2.99%) |
Show
Entries
Hunan Fangsheng Pharmaceutical Co Ltd Frequently Asked Questions
What is Hunan Fangsheng Pharmaceutical Co Ltd(SHSE:603998)'s stock price today?
The current price of SHSE:603998 is ¥10.78. The 52 week high of SHSE:603998 is ¥13.50 and 52 week low is ¥8.64.
When is next earnings date of Hunan Fangsheng Pharmaceutical Co Ltd(SHSE:603998)?
The next earnings date of Hunan Fangsheng Pharmaceutical Co Ltd(SHSE:603998) is .
Does Hunan Fangsheng Pharmaceutical Co Ltd(SHSE:603998) pay dividends? If so, how much?
The Dividend Yield %  of Hunan Fangsheng Pharmaceutical Co Ltd(SHSE:603998) is 2.79% (As of Today), Highest Dividend Payout Ratio of Hunan Fangsheng Pharmaceutical Co Ltd(SHSE:603998) was 1.13. The lowest was 0.07. And the median was 0.52. The  Forward Dividend Yield % of Hunan Fangsheng Pharmaceutical Co Ltd(SHSE:603998) is 4.64%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Hunan Fangsheng Pharmaceutical Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers